New York, USA – August 24, 2022 – Proteolysis Targeting Chimeras (PROTAC) was first proposed in 2001, which can utilize the naturally existing protein clean-up system in the body to reduce protein levels by degrading protein rather than inhibiting protein function as disease treatments. After 20 years of continuous development, PROTAC has become an emerging technology favored by research institutes and pharmaceutical companies. Moreover, the market size of PROTACs has been growing at a steady rate in the past years and is estimated to expand significantly during the forecast period from 2021 to 2028.
PROTAC is a heterobifunctional small molecule with a linker and two ligands, and this unique structure leverages its protein targeting and degradation capability. PROTACs have also demonstrated elevated benefits in the treatment of drug-resistant cancers than other therapeutic means.
Creative Biolabs is capable of developing PROTAC molecules for protein degradation with a high degree of selectivity and provides services as follows:
• Ligand design for target protein
• Ligand screening for E3 ligase
• Linker design and optimization
• PROTAC structural modification
• Custom peptide and compound synthesis
Herein, ligand screening for E3 ligases is decisive in determining the efficiency of PROTAC. So far, the most popular E3 ubiquitin ligases include the Von Hippel-Lindau disease tumor suppressor protein (VHL), the Mouse Double Minute 2 homolog (MDM2), the Cellular Inhibitor of Apoptosis Protein (cIAP), and the cereblon (CRBN).
“We studied the structure of VHL and its interaction with HIF1a and designed ligand compounds according to the structure of HIF1a peptide using the fragment screening technique. We’ve prepared corresponding PROTAC molecules of good capabilities,” said a scientist from Creative Biolabs.
Creative Biolabs is committed to designing VHL ligands in various forms, such as small molecules, peptides, and antibodies, and further investigating the interaction pattern between the VHL and ligands for further ligand development and optimization.
For MDM2-based PROTAC, Creative Biolabs employs a variety of strategies to generate different types of ligands, including but not limited to in silico screening of small molecules using structure-based computational methods, peptides, and recombinant antibodies based on phage display. Creative Biolabs can also support modifications and engineering of existing ligands to generate functional PROTACs from ligands of poor selectivity or weak affinity.
Discover more PROTAC solutions and products at https://www.creative-biolabs.com/protac.
About Creative Biolabs
As a leading service provider in biological research and drug discovery, Creative Biolabs is dedicated to PROTAC development and has launched one-stop PROTAC development services to advance small molecule drug discovery.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/protac
